摘要
目的构建肝恶性肿瘤人源性异种移植(PDX)模型,分析影响PDX模型成瘤率的相关因素,并比较原代肿瘤和PDX模型的生物学特点。方法通过手术收集新鲜肝恶性肿瘤组织样本(天津市第一中心医院),接种于BALB/c-nu小鼠皮下,分析患者临床病理信息与PDX模型成瘤率的相关性,并比较PDX模型和原代肿瘤的病理学形态和特异性蛋白的表达。结果从63例肝恶性肿瘤样本中成功构建出33例PDX模型,整体成瘤率达到52.4%(33/63),其中原发性肝癌成瘤率为46.3%(25/54),肝转移癌成瘤率为88.9%(8/9)。影响成瘤率的主要因素是患者肿瘤的病理类型、远处转移和TNM分期(均P<0.05)。PDX模型和原代肿瘤的病理学形态和组织特异性蛋白的表达相似。结论成功构建了肝恶性肿瘤PDX模型,且成瘤率较高,并能保持原代肿瘤的生物学特性。
Objective To establish the patient derived xenograft(PDX)model of liver malignant tumor,analyze the related factors affecting the carcinogenesis of PDX model,and analyze the differences of biological characteristics between the primary tumor and PDX model.Methods Fresh liver malignant tumor tissue samples were collected from the patients who received the surgery from the Tianjin First Central Hospital and the samples were inoculated subcutaneously into BALB/c-nu mice.The correlations between clinicopathological information and tumor formation rate were analyzed,and the pathological morphology and specific protein expression of PDX model and primary tumor were compared.Results Thirty-three PDX models were successfully established from 63 cases of liver malignant tumors.The overall tumor formation rate was 52.4%(33/63),including 46.3%(25/54)of primary liver cancer and 88.9%(8/9)of liver metastasis.The main factors affecting the tumor formation rate were tumor pathological type,distant metastasis and TNM stage(all P<0.05).The pathological morphology and specific protein expression of PDX model and primary tumor were similar.Conclusion The PDX model of liver malignant tumor was successfully constructed,and the tumor formation rate was high,and can maintain the biological characteristics of the primary tumor.
作者
韩品盛
杨龙
崔涛
童文
苗宇
徐策
伊秀林
张雅敏
Han Pinsheng;Yang Long;Cui Tao;Tong Wen;Miao Yu;Xu Ce;Yi Xiulin;Zhang Yamin(Clinical Medical College of Tianjin Medical University,Tianjin 300070,China;Department of Hepatological Surgery,Tianjin First Central Hospital,Tianjin 300192,China;State Key Laboratory of Drug Delivery Technology and Pharmacokinetics,Tianjin Institute of Pharmaceutical Research,Tianjin 300000,China;Research Unit for Drug Metabolism,Chinese Academy of Medical Sciences,Beijing 100730,China)
出处
《中华肝胆外科杂志》
CAS
CSCD
北大核心
2022年第4期295-298,共4页
Chinese Journal of Hepatobiliary Surgery
基金
天津市第一中心医院科技基金(2019CL01)
中国医学科学院医学与健康科技创新工程项目(2019-I2M-5-020)
天津市"项目+团队"重点培养专项(创新类)(XC202030)。
关键词
肝肿瘤
人源性异种移植
成瘤率
Liver neoplasms
Patient derived xenografts
Tumor formation rate